Latest Galveston National Laboratory Stories

2011-08-12 12:35:06

NIH awards $3 million to prepare for clinical trials; developers hope vaccine will alleviate suffering caused by mosquito-borne virus in Asia and Africa and limit its spread Researchers have developed a new candidate vaccine to protect against chikungunya virus, a mosquito-borne pathogen that produces an intensely painful and often chronic arthritic disease that has stricken millions of people in India, Southeast Asia and Africa. A single dose of the experimental vaccine protected lab mice...

2008-06-24 09:01:55

Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the University of Texas Medical Branch at Galveston (UTMB), part of the University of Texas System, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high-dose delivery of the anti-cancer agent melphalan. UTMB is the sixth center in this multi-center study testing the Delcath System. Delcath...

Word of the Day
  • Boughs or branches.
  • Warbling of birds in trees.